The Importance of Prostaglandin and Nitric Oxide Synthesis in Apical Periodontitis
NCT ID: NCT06023901
Last Updated: 2024-10-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
185 participants
INTERVENTIONAL
2021-01-07
2023-08-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exploring 8-iso Prostaglandin F2α and Adenosine Deaminase Levels in Periodontal Health and Disease
NCT06236555
Asprosın And Tumor Necrosıs Factor-α Levels In Type 2 Dıabetıc Chronıc Periodontitis
NCT06993818
Adrenomedullin Upregulation in Apical Periodontitis
NCT05297747
Evaluation of SOST, TWEAK, RANKL, OPG Levels in Smokers and Non-Smokers With Periodontitis
NCT06103578
Sclerostin Regulation in Apical Periodontitis Lesions in Apical Periodontitis Lesions
NCT06512103
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Demographic-Clinical History Gender, age, body mass index (BMI), comorbidity status of all patients participating in the study were recorded. The patients' root canal treatment (RCT), dental crown, composite/amalgam fillings (CF), number of missing teeth (NMT) findings were obtained as a result of intraoral examination.
* Periapical and Periodontal Disease Scoring All teeth present in the oral cavity were radiographed and the presence of radiolucent images associated with the periapical region and radiographic bone loss was assessed. Panoramic radiographs, in the study, were obtained using a digital panoramic unit (VistaPano S, Durr Dental AG, Germany), operating at 73kVp and 10 mA with 13500 milliseconds exposure time in standard mode. For periapical radiographs Carestream RVG 5200 (RVG; Carestream Health Inc, Atlanta, CA, USA) system was used with an x-ray unit, setting of 70 kV, 8 mA. The bisecting angle technique was applied in obtaining the periapical images. Then, the radiographs were analyzed with Kodak Dental Imaging Software. From radiographic evaluation of the teeth, the presence of periapical radiolucency without periodontal disease was considered sufficient for AP diagnosis. Abscess scoring (AS-PAI) based on the periapical index was performed as an indicator of disease progression within the AP group. For this scoring, the periapical index (PAI) scoring system,10 which is a scoring system for the radiographic evaluation of apical periodontitis, was used. Accordingly, the AP group was divided into 3 subgroups. AS-PAI 1 (mild): those having at least 1 tooth with either PAI 3 or PAI 4, AS-PAI 2 (moderate): those having only 1 tooth with a PAI 5, AS-PAI 3 (severe): those having two or more teeth with a PAI 5.
Periodontal measurements, obtained for the study, consisted of the highest probing depths (in milimetres) recorded around six selected teeth per participant. In this study, the CP group was divided into 4 subgroups according to the periodontitis staging system (PSS) (Tonetti). This system classifies the periodontitis from I to IV according to the interdental clinical attachment loss (CAL), radiographic bone loss (RBL) and tooth loss. This scoring is as follows: Stage 1: CAL 1 to 2 mm, RBL is at coronal third (\<15%) and no tooth loss, Stage 2: CAL 3 to 4 mm, RBL is at coronal third (15% to 33%) and no tooth loss, Stage 3: CAL \> 5 mm, RBL is extending to mid-third of root and beyond and tooth loss \< 4 teeth, and Stage 4: CAL \> 5 mm, RBL is extending to mid-third of root and beyond and tooth loss \> 5 teeth. However, Stage 1 and 2 were evaluated in the same group due to the low number of cases. As a result, the groups were designed as Stage 1-2: PSS 1-2, Stage 2: PSS 2 and Stage 3: PSS 3.
• Collection of Venous Blood and Gingival Crevicular Fluid (GCF) Fasting (8-10 hours) venous blood of all participants was taken from forearm antecubital/basic veins. After keeping the blood at room temperature for 30 minutes, it was centrifuged at 2500 xg for 10 minutes. After centrifugation, the upper serum of the tubes was separated. Hemolysis indices (HI) of the sera were measured to prevent optical interference. (Cobas 8000 Chemistry Analyzer, USA). Those with a hemolysis index greater than 50 (mg/dl Hb) were excluded from the study. Appropriate sera were stored at -80oC until the day of analysis. In addition to venous blood, gingival crevicular fluid (GCF) samples were also collected and were stored at -80oC under similar conditions. On the day of analysis, all serums and GCF were first allowed to dissolve slowly at +4 oC and then brought to room temperature before measurement.
Gingival crevicular fluid samples were taken prior to periodontal probing to avoid contamination by blood. To avoid contamination of the sample, patients were asked not to eat or drink anything for at least 30 minutes before the procedure. Three samples were taken from the mesial, distal and buccal surfaces of related tooth. The selected sites were isolated with cotton roll and supragingival plaque, if present, was removed using a curette to prevent saliva and/or plaque contamination. GCF was collected for 60 seconds using PerioPaper strips (OraFlow Inc., NY, USA) placed gently until slight resistance was felt. The three samples were pooled into Eppendorf tubes and then placed in the laboratory freezer at -80 °C for storage. Periopapers were thoroughly washed in 0.5 ml eppendorf Tubes (after subtracting the tare weight of the tube) with 100 µl of phosphate-buffered saline (PBS) using an automatic pipette. Blood-stained paper strips were removed from the samples. All GCF samples were weighed on a precision balance (Shimadzu Libror, Model AEG-220, Germany) and recorded. All samples were thoroughly mixed with a 15-20 sec vortex device (Heidolph Reax Top Vortex, Schwabach, Germany). This allowed GCF to pass into PBS. The paper strips were removed without contaminating the samples and the remaining extract was stored in the freezer until the working day. The results obtained on the study day were proportioned by weights/PBS.
• Biochemical Analyzes TNF-α, IL-10, NO and PGE2 levels in the sera of all patients were measured in Microplate ELISA Reader (BioTek Epoch 2 Microplate ELISA Reader, USA) using the ELISA method. Due to the insufficient amount of sample (100 µl), only NO and PGE2 levels were measured in the GCF using the same ELISA kit.
Serum TNF-α, IL-10, NO and PGE2 levels were analyzed using ELISA plates whose wells were pre-coated with antibody (human TNF-α, IL-10, NO or PGE2). The sensitivity of TNF-α, IL-10, NO and PGE2 test kits (Bioassay Technology Laboratory, China) is 1.52 ng/L, 2.59 pg/mL, 1.12 µmol/L and 1.28 ng/L, measuring range 3-900 ng/L, respectively, 5-1500 pg/mL, 2-600 µmol/L and 2-600 ng/L, CV for all tests for intraassay and interassay were \< 10%.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
85 patients with only apical periodontitis (AP group)
AP group was divided into 3 subgroups. AS-PAI 1 (mild): those having at least 1 tooth with either PAI 3 or PAI 4, AS-PAI 2 (moderate): those having only 1 tooth with a PAI 5, AS-PAI 3 (severe): those having two or more teeth with a PAI 5.
Apical periodontitis
Radiography of the patients were taken. Blood samples were collected from those patient
50 patients with only chronic periodontitis (CP group),
In this study, the CP group was divided into 4 subgroups according to the periodontitis staging system (PSS) (Tonetti). This system classifies the periodontitis from I to IV according to the interdental clinical attachment loss (CAL), radiographic bone loss (RBL) and tooth loss. This scoring is as follows: Stage 1: CAL 1 to 2 mm, RBL is at coronal third (\<15%) and no tooth loss, Stage 2: CAL 3 to 4 mm, RBL is at coronal third (15% to 33%) and no tooth loss, Stage 3: CAL \> 5 mm, RBL is extending to mid-third of root and beyond and tooth loss \< 4 teeth, and Stage 4: CAL \> 5 mm, RBL is extending to mid-third of root and beyond and tooth loss \> 5 teeth. However, Stage 1 and 2 were evaluated in the same group due to the low number of cases. As a result, the groups were designed as Stage 1-2: PSS 1-2, Stage 2: PSS 2 and Stage 3: PSS 3.
Apical periodontitis
Radiography of the patients were taken. Blood samples were collected from those patient
A healthy control group of 50 volunteers
control group. A healthy control group of 50 volunteers without periodontal pathology as well as any acute/chronic disease (muscle/joint/bone diseases, inflammatory bowel disease, local or generalized infection, severe organ disease, cardiovascular disease and diabetes mellitus) were included in the study.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Apical periodontitis
Radiography of the patients were taken. Blood samples were collected from those patient
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who had taken antibiotics and/or anti-inflammatory drugs within the last 6 months - - Without periodontal pathology as well as any acute/chronic disease (muscle/joint/bone diseases, inflammatory bowel disease, local or generalized infection, severe organ disease, cardiovascular disease and diabetes mellitus) were included in the study
Exclusion Criteria
* with a history of using steroid or nonsteroidal anti-inflammatory drugs and high-dose biotin vitamin in the last 48 hours were excluded from the study.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Istanbul Medipol University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Seyda Ersahan, DDS, PhD
Principal Investigator, Clinical Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Istanbul Medipol University, Faculty of Dentistry
Istanbul, ESENLER, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E-10840098-772.02-2860/344
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.